Challenges Remain to be Addressed With CAR T-Cell Therapy in DLBCL
Bianca D. Santomasso, MD, PhD, discusses the challenges that exist for the treatment of patients with diffuse large B-cell lymphoma with CAR T-cell therapy.
Related Articles
COMMANDS Trial: Luspatercept Efficacy and Long-Term Outcomes in ESA-Naive Lower-Risk MDS
A panelist highlights that updated COMMANDS trial data demonstrate luspatercept’s robust efficacy in erythropoiesis-stimulating agent–naive patients with low-risk myelodysplastic syndrome—achieving high rates of durable transfusion…
Ponatinib Shows Promise in PhALLCON Study for Ph+ ALL Treatment
Ponatinib improved MRD negativity and safety in Ph+ ALL patients in the PHALLcon study, supporting its role as a potent TKI despite long-term data pending.
FDA Grants Orphan Drug Designation to SH-110, a Liquid Glioma Therapy
The FDA designates SH-110 as an orphan drug, offering a safer oral treatment option for glioma patients with swallowing difficulties.
Tabelecleucel Advances in EBV+ PTLD With Phase 3 Trial and FDA Resubmission
Pierre Fabre leads global development of tab-cel, an innovative therapy for EBV+ PTLD, with ongoing trials and potential FDA approval on the horizon.
Dr Ghia on Long-Term Benefits of Fixed-Duration Ibrutinib/Venetoclax in CLL
Paolo Ghia, MD, PhD, discusses the takeaways from the final analysis of the phase 2 CAPTIVATE study in CLL.
MIDAS Trial: ASCT Offers No MRD Benefit Over Isa-KRd in Myeloma
In the MIDAS trial, ASCT showed no added MRD benefit over Isa-KRd in newly diagnosed myeloma, raising questions about transplant timing.
Fixed-Duration Ibrutinib/Venetoclax Shows Durable Responses in CLL, Says Dr Ghia
New findings reveal that fixed-duration ibrutinib plus venetoclax offers long-term efficacy and safety for patients with untreated chronic lymphocytic leukemia.
Five-Year Data Highlights Cilta-Cel’s Impact in Myeloma, Says Dr Voorhees
Peter M. Voorhees, MD, discusses the 5-year follow-up results from the CARTITUDE-1 trial of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.
Patients With Low-Risk Thyroid Cancer Can Potentially Avoid Post-Surgery Radiation
New research suggests that certain patients with low-risk thyroid cancer can safely forgo postoperative radioiodine ablation without compromising long-term outcomes.
Predictive Model Aims to Personalize Hodgkin Lymphoma Treatment
A new risk model uses objective clinical data to predict cure or relapse in Hodgkin lymphoma, with future plans to guide treatment and survivorship care.